Processing Magazine

Celgene buying Gloucester Pharma for $640 million

December 8, 2009
The Associated Press reports biotechnology company Celgene Corp. will buy privately held Gloucester Pharmaceuticals Inc. for $640 million, giving them access to key cancer drugs. The deal includes $340 million in cash upfront and $300 million in future regulatory milestone payments. The Food and Drug Administration approved Gloucester''s drug Istodax in November as a treatment for cutaneous T-cell lymphoma. It is approved only for patients who were on at least one previous therapy. Gloucester is seeking other approvals, and European regulators are reviewing Istodax. The company is testing drugs for cutaneous T-cell lymphoma and peripheral T-cell lymphoma, which are both types of non-Hodgkin''s lymphoma. It is also developing combinations of drugs for solid tumors and for multiple myeloma. Celgene''s drugs include Revlimid, which is used against multiple myeloma, non-Hodgkin''s lymphoma and chronic lymphocytic leukemia; and Vidaza, which is approved for treatment of the bone marrow disease myelodysplastic syndrome and acute myeloid leukemia.